[{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Legend Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Legend Biotech"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ GSK"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Ciltacabtagene Autoleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0.65000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.65000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Janssen Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Janssen Biotech"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"GenScript Biotech Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ GenScript Biotech Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ GenScript Biotech Corporation"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Ciltacabtagene Autoleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0.65000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.65000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Legend Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Legend Biotech"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"Bortezomib","moa":"||Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0.34999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.34999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Morgan Stanley","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Morgan Stanley"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"JNJ-4528","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase III","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Legend Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"||Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"JNJ-4528","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase III","graph3":"Legend Biotech","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Legend Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ GSK"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"LB1901","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"LB1901","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LB1901","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LB1908","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Legend Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"LCAR-M61S Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Legend Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Legend Biotech \/ Legend Biotech"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Centocor","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Phase III","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Legend Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Legend Biotech \/ Legend Biotech"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"LB2102","moa":"DLL3","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"LB2102","moa":"DLL3","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":1.1100000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.1100000000000001,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"LB2102","moa":"DLL3","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":1.1100000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.1100000000000001,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LB1908","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Legend Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"LCAR-C18S Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Legend Biotech \/ Legend Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Legend Biotech"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Legend Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"LCAR-BCX Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Legend Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Legend Biotech"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Legend Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"LCAR-T2C CAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Legend Biotech \/ Legend Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Legend Biotech"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Legend Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LCAR-AIO Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Legend Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Legend Biotech"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Legend Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LCAR-AIO Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Legend Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Legend Biotech"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Legend Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LCAR-BCDR Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Legend Biotech \/ Legend Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Legend Biotech"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Legend Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LUCAR-B68 Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Legend Biotech \/ Legend Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Legend Biotech"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Legend Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LCAR-AMDR Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Legend Biotech \/ Legend Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Legend Biotech"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Legend Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"LCAR-G08 Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Legend Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Legend Biotech"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Legend Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"LUCAR-G39P Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Legend Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Legend Biotech"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Legend Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"LUCAR-G39D Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Legend Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Legend Biotech"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Legend Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"LCAR-HL30 Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Legend Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Legend Biotech"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"LCAR-AIO T Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Legend Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"LCAR-AIO T Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Legend Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Legend Biotech"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LB2102","moa":"DLL3","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Legend Biotech
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
